Table 4 Multivariable Cox proportional hazard regression analyses for subsequent breast cancer in female 5-year childhood cancer survivors whose treatment history did not include chest radiotherapy nor alkylating agent chemotherapy (primary cancer diagnosis year 1946–2012)a

From: Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer

 

Total (n)

%

No. of SBC (n)

%

HRb

95% CI

Cumulative doxorubicin dose (mg m−²)

0

5,880

90.5

61

71.8

1.0

Ref.

<300c

305

4.7

7

8.2

2.35

0.96–5.71

300–399

131

2.0

5

5.9

2.67

1.08–6.59

≥400

136

2.1

8

9.4

3.58

1.66–7.71

Unknown

47

0.7

4

4.7

–

–

Daunorubicin

No

6,020

92.6

81

95.3

1.0

Ref.

Yes

479

7.4

4

4.7

1.43

0.48–4.24

Epirubicin

No

6,362

97.9

84

98.8

1.0

Ref.

Yes

137

2.1

1

1.2

3.46

0.41–29.10

  1. aIn total, 6,499 female 5-year survivors did not receive chest radiotherapy nor alkylating agent chemotherapy, among whom 85 developed SBC during follow-up.
  2. bModels were further adjusted for pelvic radiotherapy ≥5 Gy (yes/no) and age at primary childhood cancer diagnosis (categorical variable).
  3. cThe cumulative doxorubicin dose (mg m−2) categories <100 (0 case/46 survivors), 100–199 (1 case/129 survivors) and 200–299 (6 cases/130 survivors) were collapsed due to low numbers of SBC cases.
Back to article page